Ticker

No recent analyst price targets found for ONCO.

Latest News for ONCO

Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation

Realbotix Robots and AI to Deploy in Evidence-Based Pilot Designed to Improve Wellbeing and Address Loneliness Among Older Adults in UK Care Settings; Realbotix Becomes Accredited Supplier on Bloom's Public Sector Marketplace; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, July 07, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq:…

GlobeNewsWire • Jul 7, 2026
Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010

VANCOUVER, BC / ACCESS Newswire / June 23, 2026 / Onco-Innovations Limited (NEO:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered into a services agreement with Nanosoft Polymers ("Nanosoft"), a specialized polymer engineering and drug delivery company, to support the continued development of ONC010, the Company's lead nanoparticle-formulated…

Accesswire • Jun 23, 2026
Onco-Innovations Announces Non-Brokered LIFE Offering

Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire / June 19, 2026 / Onco-Innovations Limited (CBOE:ONCO) ("Onco" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement (the "Private Placement") of units of the Company (each, a "Unit"), pursuant to which it will offer 6,764,069 Units at a price…

Accesswire • Jun 19, 2026
Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development

Also Announces Appointment of Mr. Dave Antony as CFO VANCOUVER, BC / ACCESS Newswire / June 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN:A3EKSZ) ("Onco" or the "Company") announced the successful completion of a 300-gram scale-up batch of A83B4C63, the active pharmaceutical ingredient ("API") underpinning the Company'sproprietary drug candidate, ONC010 (the "PNKP Inhibitor…

Accesswire • Jun 19, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for ONCO.

No House trades found for ONCO.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top